% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Mayerhoefer:302119,
      author       = {M. E. Mayerhoefer and A. Kienzle$^*$ and S. Woo and H. A.
                      Vargas},
      title        = {{U}pdate on {L}iquid {B}iopsy.},
      journal      = {Radiology},
      volume       = {315},
      number       = {3},
      issn         = {0033-8419},
      address      = {Oak Brook, Ill.},
      publisher    = {Soc.},
      reportid     = {DKFZ-2025-01251},
      pages        = {e241030},
      year         = {2025},
      abstract     = {Liquid biopsy helps detect cells and cell-derived
                      metabolites, proteins, nucleic acids, and vesicles that are
                      shed into body fluids by tumors. This diagnostic test
                      requires only approximately 10 mL of blood or urine. It has
                      received considerable attention as a minimally invasive tool
                      for whole-body tumor interrogation for use in patients with
                      cancer. It poses an attractive and potentially
                      cost-effective alternative to invasive tissue sampling
                      through tissue biopsies, especially serial assessments, such
                      as for treatment response evaluation and mutations that
                      occur during cancer treatment. Cell-free and circulating
                      tumor DNA are the most frequently tested liquid biopsy
                      analytes, and have shown promise for cancer screening,
                      assessment of residual disease after treatment, and clinical
                      outcome prediction and prognostication. Whereas liquid
                      biopsy is less sensitive than imaging in early tumor stages,
                      it is more specific and may help detect treatment response
                      earlier than the Response Evaluation Criteria in Solid
                      Tumors, or RECIST. Aimed primarily at radiologists, this
                      review article provides an update on recent developments in
                      the use of liquid biopsy, including findings from landmark
                      clinical trials and U.S. regulatory approvals as companion
                      diagnostic tests for clinical use, particularly in four
                      malignancies: lymphoma, breast cancer, prostate cancer, and
                      melanoma. Finally, current challenges for the clinical
                      implementation of liquid biopsy are discussed.},
      subtyp        = {Review Article},
      keywords     = {Humans / Liquid Biopsy: methods / Neoplasms: pathology /
                      Neoplasms: diagnosis / Biomarkers, Tumor: blood /
                      Circulating Tumor DNA: blood / Biomarkers, Tumor (NLM
                      Chemicals) / Circulating Tumor DNA (NLM Chemicals)},
      cin          = {D410},
      ddc          = {610},
      cid          = {I:(DE-He78)D410-20160331},
      pnm          = {314 - Immunologie und Krebs (POF4-314)},
      pid          = {G:(DE-HGF)POF4-314},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40525978},
      doi          = {10.1148/radiol.241030},
      url          = {https://inrepo02.dkfz.de/record/302119},
}